한글목차

세계의 줄기세포 치료 시장은 2030년까지 11억 달러에 달할 전망

2023년에 3억 7,930만 달러로 추정된 세계의 줄기세포 치료 시장은 2030년에는 11억 달러에 달하며, 분석 기간인 2023-2030년의 CAGR은 16.4%로 성장할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 동종 줄기세포 치료는 CAGR 16.7%를 기록하며, 분석 기간 종료까지 10억 달러에 달할 것으로 예측됩니다. 자가 줄기세포 치료 부문의 성장률은 분석 기간 중 CAGR 10.0%로 추정됩니다.

미국 시장은 1억 440만 달러로 추정, 중국은 CAGR 15.5%로 성장할 것으로 예측

미국의 줄기세포 치료 시장은 2023년에 1억 440만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 1억 6,560만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년의 CAGR은 15.5%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 14.3%와 13.8%로 예측됩니다. 유럽에서는 독일이 CAGR 11.5%로 성장할 것으로 예측됩니다.

세계의 줄기세포 치료 시장 - 주요 동향과 촉진요인 정리

줄기세포 치료는 어떻게 환자 케어에 혁명을 초래하는가?

줄기세포 치료는 줄기세포를 이용해 손상된 조직을 재생하고 질병을 치료하고 환자의 기능을 회복시키는 것입니다. 혈액질환, 자가면역질환, 정형외과적 손상, 신경퇴행성 질환 등 다양한 질환에 사용되고 있습니다. 줄기세포의 재생 능력은 대증요법을 넘어선 치료의 가능성을 제공함으로써 현대 의료에 필수적인 요소로 자리매김하고 있습니다. 질병과 치료법에 따라 자가(환자 유래) 줄기세포와 동종(공여자 유래) 줄기세포를 사용하여 치료할 수 있습니다. 의학계가 재생의료와 맞춤치료에 주목하는 가운데, 줄기세포 치료는 급성 및 만성질환에 대한 유망한 해결책으로 떠오르고 있습니다.

줄기세포 치료 시장의 주요 부문은?

주요 유형로는 동종 줄기세포치료와 자가 줄기세포치료가 있으며, 동종 줄기세포치료는 혈액악성종양, 면역질환, 유전성 질환 등의 치료에 광범위하게 사용되고 있으며, 큰 시장 점유율을 차지하고 있습니다. 용도로는 정형외과, 신경과, 순환기내과, 혈액내과, 자가면역질환 등이 있으며, 그 중 혈액내과는 백혈병, 림프종 및 기타 혈액질환 치료에서 줄기세포 이식의 효과에 힘입어 주요 분야로 부상하고 있습니다. 최종사용자에는 병원, 연구기관 및 전문 클리닉이 포함되며, 병원은 입원 및 외래 치료 모두에서 최첨단 줄기세포 치료를 제공하므로 시장을 선도하고 있습니다.

줄기세포 치료는 어떻게 헬스케어에 통합되고 있는가?

정형외과에서 줄기세포 치료는 관절 손상, 연골 손상, 힘줄 회복에 사용되어 조직 재생을 촉진하고 통증을 감소시키며 운동 능력을 향상시킵니다. 신경학에서 줄기세포는 파킨슨병, 척수 손상, 뇌졸중 회복과 같은 질병에 대해 손상된 신경세포를 대체하고 신경 회복을 지원함으로써 치료 가능성을 제공합니다. 심장병학에서 줄기세포 치료는 심장마비 후 심장 조직 재생을 목표로 심장 기능 개선과 합병증 감소를 목표로 하고 있습니다. 또한 다발성 경화증이나 전신성 홍반성 루푸스와 같은 자가면역질환은 줄기세포 이식을 통해 면역체계를 재설정하고 장기적인 완화를 유도하여 치료할 수 있습니다.

줄기세포치료제 시장의 성장을 가속하는 요인은 무엇인가?

줄기세포 치료 시장의 성장은 신경 퇴행성 질환, 심부전, 면역 질환 등 치료법이 제한적인 질환에 대한 재생 치료에 대한 수요 증가 등 여러 요인에 의해 주도되고 있습니다. 줄기세포 연구, 임상 프로토콜 및 전달 방법의 발전은 이러한 치료법의 안전성, 유효성 및 접근성을 향상시켜 의료 분야에서 폭넓은 채택을 촉진하고 있습니다. 줄기세포 치료는 환자별 병태생리 및 유전자 프로파일에 기반한 맞춤형 치료를 가능하게 함으로써 맞춤의료와 맞춤형 치료의 중요성이 부각되면서 수요가 더욱 증가하고 있습니다. 또한 규제 당국의 승인 확대, 임상시험 성공률 증가, 생명공학 및 재생의료에 대한 투자 증가 등이 시장 개척에 기여하며 줄기세포 치료제의 개발 및 상용화를 가속화하고 있습니다.

부문

유형(동종 이식, 자가 이식);세포원(지방조직 유래 MSC, 골수 유래 MSC, 태반/제대 유래 MSC, 기타 세포원);용도(근골격계 질환, 창상·상해, 심혈관계 질환, 소화기계 질환, 기타 용도)

조사 대상 기업의 예(주목 12사)

• Advanced Cell Technology
• Anterogen, Ltd.
• Biotime, Osiris Therapeutics
• Cynata
• Cytori Therapeutics
• HolostemTerapieAvanzateS.r.l.
• Human Longevity
• JCR Pharmaceuticals
• Medipost
• Mesoblastand AlloSource
• NuVasive
• Osiris Therapeutics, Inc.
• Pharmicell
• Promethera Biosciences
• RTI Surgical
• Stemcell Technologies

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Stem Cell Therapy Market to Reach US$1.1 Billion by 2030

The global market for Stem Cell Therapy estimated at US$379.3 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 16.4% over the analysis period 2023-2030. Allogeneic Stem Cell Therapy, one of the segments analyzed in the report, is expected to record a 16.7% CAGR and reach US$1.0 Billion by the end of the analysis period. Growth in the Autologous Stem Cell Therapy segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$104.4 Million While China is Forecast to Grow at 15.5% CAGR

The Stem Cell Therapy market in the U.S. is estimated at US$104.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$165.6 Million by the year 2030 trailing a CAGR of 15.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.3% and 13.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.5% CAGR.

Global Stem Cell Therapy Market - Key Trends and Drivers Summarized

How Is Stem Cell Therapy Revolutionizing Patient Care?

Stem cell therapy involves the use of stem cells to regenerate damaged tissues, treat diseases, and restore function in patients. It is used for a wide range of conditions, including hematological disorders, autoimmune diseases, orthopedic injuries, and neurodegenerative diseases. Stem cells, due to their regenerative capabilities, offer the potential for curative treatments that go beyond symptomatic relief, making them an integral part of modern healthcare. The therapy can involve autologous (patient-derived) or allogeneic (donor-derived) stem cells, depending on the condition and the treatment approach. As medical science focuses on regenerative and personalized treatments, stem cell therapy has emerged as a promising solution for both acute and chronic conditions.

What Are the Key Segments in the Stem Cell Therapy Market?

Key types include allogeneic and autologous stem cell therapies, with allogeneic therapies holding a significant market share due to their broader use in treating conditions like hematological malignancies, immune disorders, and inherited diseases. Applications cover orthopedics, neurology, cardiology, hematology, and autoimmune diseases, with hematology representing a major segment driven by the effectiveness of stem cell transplants in treating leukemia, lymphoma, and other blood disorders. End-users include hospitals, research institutes, and specialty clinics, with hospitals leading the market as they provide advanced stem cell therapies for both inpatient and outpatient care.

How Is Stem Cell Therapy Integrated Across Healthcare?

In orthopedics, stem cell therapy is used to treat joint injuries, cartilage damage, and tendon repair by promoting tissue regeneration, reducing pain, and improving mobility. In neurology, stem cells offer potential treatments for conditions like Parkinson’s disease, spinal cord injuries, and stroke recovery by replacing damaged neurons and supporting neural repair. In cardiology, stem cell therapy targets heart tissue regeneration following heart attacks, aiming to improve cardiac function and reduce complications. Additionally, autoimmune diseases like multiple sclerosis and systemic lupus erythematosus are treated with stem cell transplants that reset the immune system and provide long-term remission.

What Factors Are Driving the Growth in the Stem Cell Therapy Market?

The growth in the Stem Cell Therapy market is driven by several factors, including increasing demand for regenerative treatments that address conditions with limited curative options, such as neurodegenerative diseases, heart failure, and immune disorders. Advancements in stem cell research, clinical protocols, and delivery methods have improved the safety, efficacy, and accessibility of these therapies, supporting wider adoption across medical fields. The focus on personalized medicine and tailored treatments has further fueled demand, as stem cell therapy enables individualized care based on patient-specific conditions and genetic profiles. Additionally, growing regulatory approvals, increased clinical trial success rates, and rising investments in biotechnology and regenerative medicine have contributed to market growth, accelerating the development and commercialization of stem cell therapies.

SCOPE OF STUDY:

The report analyzes the Stem Cell Therapy market in terms of US$ by the following Application; Cell Source; Type, and Geographic Regions/Countries:

Segments:

Type (Allogeneic, Autologous); Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs, Other Cell Sources); Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 12 Featured) -

• Advanced Cell Technology
• Anterogen, Ltd.
• Biotime, Osiris Therapeutics
• Cynata
• Cytori Therapeutics
• HolostemTerapieAvanzateS.r.l.
• Human Longevity
• JCR Pharmaceuticals
• Medipost
• Mesoblastand AlloSource
• NuVasive
• Osiris Therapeutics, Inc.
• Pharmicell
• Promethera Biosciences
• RTI Surgical
• Stemcell Technologies

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Stem Cell Therapy - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Chronic Diseases Drives Demand for Stem Cell Therapy
  • Increasing Focus on Regenerative Medicine Spurs Growth in Stem Cell Therapy
  • Advancements in Cell-Based Immunotherapies Propel Market Expansion
  • Rising Adoption in Neurological Disorders Expands Addressable Market
  • Growing Use in Hematological Disorders Strengthens Business Case
  • Expansion of Cardiovascular Applications Spurs Demand for Stem Cell Therapy
  • Emergence of Off-the-Shelf Allogeneic Therapies Enhances Adoption
  • Growing Focus on Rare Disease Treatment Expands Market Potential
  • Rising Approvals for Clinical Trials Accelerates Demand for Stem Cell Therapy
  • Advancements in Gene-Edited Stem Cells Propel Therapeutic Opportunities
  • Rising Focus on Age-Related Degenerative Conditions Fuels Demand
  • Growing Interest in Autologous Therapies Expands Adoption
  • Emergence of Combination Therapies Strengthens Stem Cell Market
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 3: World 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 6: World 16-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 9: World 16-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 12: World 16-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 15: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 18: World 16-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 21: World 16-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 24: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 27: World 16-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 30: World 16-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 33: World 16-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 34: World Stem Cell Therapy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Placental / Umbilical Cord-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 37: World 16-Year Perspective for Placental / Umbilical Cord-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• JAPAN
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• CHINA
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 70: China 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 73: China 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• EUROPE
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• FRANCE
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 91: France 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 94: France 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• GERMANY
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Rest of Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 124: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Europe 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Stem Cell Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Asia-Pacific Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 133: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Asia-Pacific Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 136: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 139: Asia-Pacific 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of World Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of World 16-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2014, 2024 & 2030
  • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Rest of World Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 145: Rest of World 16-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2014, 2024 & 2030
  • TABLE 146: Rest of World Recent Past, Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Rest of World Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
  • TABLE 148: Rest of World 16-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Placental / Umbilical Cord-Derived MSCs and Other Cell Sources for the Years 2014, 2024 & 2030

IV. COMPETITION